CCCC Stock — C4 Therapeutics Inc

C4 Therapeutics Inc (CCCC)

Updated October 16, 2026.

CCCC is a Stock. Total return is -89.2% over the past 6 years, 237.1 points behind SPY at 147.9%.

C4 Therapeutics is a clinical-stage biopharmaceutical company developing novel protein degrader therapeutics targeting disease-causing proteins, with lead candidate Cemsidomide in development for multiple myeloma and additional programs in oncology and neuroinflammation. The company does not currently distribute dividends. C4 Therapeutics appeals primarily to growth-oriented investors with risk tolerance for early-stage biotech development, as the company remains pre-revenue while advancing its pipeline through clinical trials and strategic partnerships with major pharmaceutical firms including Roche and Merck.

CCCC performance versus SPY

Price and return data through 2026-10-16.

Total return is -89.2% over the past 6 years, 237.1 points behind SPY at 147.9%. Over the past year its total return — price change plus distributions reinvested — is 11.5%. Its deepest 1-year drawdown was 44.1%.

CCCC key facts

Asset type

Stock

Asset class

Equity

Inception date

10/02/2020

Distribution frequency

None

Last close

$2.77 (as of 2026-10-16)

Market cap

$340,164,501

Average volume

2359296.0

Beta

3.084

Payout ratio

0.0%

EPS

$-0.91

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

CCCC risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 44.1%.

Who may consider CCCC — and who may not

It is a weaker fit for investors who need monthly cash flow (CCCC does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on CCCC

• All tickers starting with C

Tagged: Healthcare.

Frequently asked questions